Kenvue is guiding for $1.10 to $1.20 in 2024 earnings per share and 2% to 4% organic sales growth. If it achieves the ...

On Oct. 21, news broke that Starboard Value took a position in Kenvue. The firm thinks there is an opportunity to improve ...

The pharmaceutical company’s stock is relatively cheap, representing an opportunity for patient value investors.

Pfizer Inc.’s stock dipped 2.5% Thursday as the company’s battle with activist shareholder Starboard Value heated up, after two former executives for the pharma giant said they would not ...

As the Murdochs take their succession battle to court, industry insiders warn the end of the dynasty may be in sight.

Pfizer CEO Albert Bourla is in a tough spot as activist investor Starboard Value continues to call for a change in the ...

The growth rate of the consumer healthcare business could accelerate now that an activist investor is involved.

(Reuters) -Hedge fund Starboard Value has taken a stake in Kenvue, the consumer products company that makes Band-Aid, ...

Despite that cash windfall, Pfizer has "dramatically underperformed its peers and the market since 2019," according to ...

Michela Tindera But despite losing Read and D’Amelio’s support, Starboard is still pushing ahead with its campaign. Yesterday, October 22nd, at an activist investor conference in New York, Starboard ...

Corvex Management LP has taken a stake in Fortrea Holdings Inc., a clinical trials management company that was spun out of ...

Adds Kenvue comment. Kenvue (NYSE:KVUE) needs to focus on fixing its skin, health and beauty segments, Jeff Smith, founder ...